Skip to content
DraconiticResearch
Search Sources API
210,089 studies31 sourcesUpdated 35 min ago

Oncology

5,305 studies560 in 7 days2,549 in 30 days

Filters
Type
Date
Clear

Latest

5,305 studies

  1. BCL2A1 marks an early, less-exhausted CD8+ tumor-infiltrating lymphocyte state associated with PD-1 blockade response in NSCLC
    Hoang Minh Quan Pham, Chia-Ling Chen, Po-Hao Feng +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  2. Myeloid-driven immunosuppression as a context-dependent therapeutic bottleneck in pancreatic ductal adenocarcinoma
    Kai Sun, Lei Yang, Jingjing Li +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  3. Antibody–drug conjugates in advanced small-cell lung cancer: a systematic review and single-arm meta-analysis of later-line monotherapy
    Xinmiao Chen, Shaoxun Li, Huiying Li
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. The Adipovascular Unit in Lipedema: A Framework for Regional Adipose Tissue Dysregulation.
    Jörg Faulhaber, C William Hanke, Martin Barsch +1
    CellsPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  5. Prognosis and Therapies in Non-Clear Cell Renal Cell Carcinomas.
    Trilok Shrivastava, Yusra Medik, Nikhila Sampath Kumar +2
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  6. Choosing Between Anti-TROP2 ADCs in Advanced Breast Cancer Without Head-to-Head Evidence: A Practical Evidence-Informed Decision Framework Endorsed by the Polish Society of Clinical Oncology.
    Piotr J Wysocki, Katarzyna Pogoda, Ewa Wysocka +2
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  7. Belgian validation of the INFLUENCE 3.0 model predicting 5-year locoregional and contralateral breast cancer recurrence.
    Aline van der Vorst, Carlijn Grimberg, Marissa C van Maaren +4
    Breast (Edinburgh, Scotland)Peer-reviewedCC BYFull textOncologyEurope PMC
  8. Intratumoral Immunotherapy-The Future of Treating Merkel Cell Carcinoma?
    Nayonika Pande, Justin C Moser, Sanjay Chandrasekaran +3
    CancersPeer-reviewedCC BYFull textOncologyEurope PMCCrossref
  9. Organ-Specific Phenolic Specialization and Antioxidant Responses in Crocus cancellatus: LC–MS/MS and Multivariate Analysis
    Bedrettin Selvi
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  10. Prehabilitation as a Strategy to Modulate the Tumor Microenvironment in Pancreatic Cancer
    Sanjna Sandeep, Jason Schutt, Kelvin Allenson +4
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  11. Potent Antineoplastic Activity against Breast Cancer in Vitro and in Vivo of a Chloro-Substituted Polyaromatic Platinum(II) Complex and Its Platinum(IV) Prodrug
    Omar Hammoud, Maria George Elias, Amjad Slika +7
    ACS OmegaPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossrefEurope PMC
  12. Optimising ovarian cancer care: An embedded mixed methods evaluation of a national nurse-led telehealth program.
    Patsy Yates, Wei-Hong Liu, Vanissa Ong +5
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerPeer-reviewedCC BYFull textOncologyEurope PMC
  13. Tailoring Escalated Adjuvant Chemotherapy for Multifocal and Multicentric Breast Cancer With Low Tumor Burden.
    Yonghui Su, Jiaqi Ying, Zhuozhao Zhan +4
    JCO precision oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  14. Getting to the Root of miRNA-Mediated Gene Silencing
    Ana Eulalio, Eric Huntzinger, Elisa Izaurralde
    CellPeer-reviewedLicence not statedFull text1,077 citedOncologyHAL
  15. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
    Julie Delyon, Lucie Biard, Marion Renaud +12
    Lancet OncologyPeer-reviewedLicence not stated72 citedOncologyHAL
  16. A cytidine deaminase biodegrader sensitises multiple cancer types to deoxycytidine analogue-based chemotherapies
    Marie Sorbara, Margot Cristol, Charlène Lopez +15
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossrefHALPMC
  17. Early and late CTCAE and patient-reported outcomes following breast radiotherapy in the REQUITE cohort
    Tina Bockstiegel, Adam Webb, Miguel E. Aguado-Barrera +42
    Clinical and Translational Radiation OncologyPeer-reviewedCC BY 4.0Full textOncologyPMCEurope PMC
  18. KSHV K15 genetic heterogeneity is associated with Kaposi sarcoma aggressiveness through modulation of the host inflammatory microenvironment
    Yu Zhang, Peng Wang, Jingzhan Zhang +4
    PLOS PathogensPeer-reviewedCC BYFull textOncologyPLOSEurope PMC
  19. A joint mixture Tobit method with latent microbial abundance improves detection of microbiome–disease associations in zero-inflated data
    Junrong Deng, Dong Chen, Siyuan Shen +5
    PLOS Computational BiologyPeer-reviewedCC BYFull textOncologyPLOSEurope PMC
  20. Integrative methylome and transcriptome analyses identify LHX3 as an epigenetically downregulated marker with tumor suppressive properties in breast cancer
    Kokab Farooq, Sheereen Gull, Zubia Farooq +5
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS
  21. Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project
    Ilaria Durosini, Dario Monzani, Veronica Coppini +43
    PLOS Digital HealthPeer-reviewedCC BY 4.0Full textOncologyPsychiatry & mental healthPLOS
  22. Stakeholder perspectives on telemedicine acceptance and experiences in Uganda: A qualitative study
    Irene Semakula, Sande Slivesteri, Benjamin Mwesige +3
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textOncologyPLOS
  23. Ten simple rules for preparing and delivering effective funding pitches in competitive grant applications
    Andy Göbel, Tilman D. Rachner
    PLOS Computational BiologyPeer-reviewedCC BY 4.0Full textOncologyPLOS
  24. Clinical utility of combining the C-reactive protein-to-albumin ratio and systemic immune-inflammation index for prognostic assessment in metastatic renal cell carcinoma
    Nobuhito Muramoto, Masayoshi Nagata, Hisashi Hirano +7
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS
  25. Predicting red breast syndrome after ADM-assisted breast reconstruction: An exploratory scoring model using routine hematologic markers
    Dong Hun Lee, Kyung Do Byun, Tae Hyun Kim +3
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS